Signal regulatory protein (SIRP)-α1 is a myeloid inhibitory immunoreceptor. SIRPα1 expression is significantly reduced in the majority of myeloid malignancies. SIRPα1 is a negative regulator of signaling and the reduced expression is considered to play a role in the pathogenesis of these diseases through aberrant signaling, but the biological roles of SIRPα1 remain largely unknown. In this study, by using SIRP-α1-knockdown chronic myeloid leukemia K562 (K562SIRP-α1KD) cells, I found that in low (0.1, 0.3%) serum media, the cell growth was increased until day 5, whereas control cells did not proliferate beyond day 2 under the same serum conditions. Consistently, in K562SIRP-α1KD cells, 2 days of culture in 0.3% serum increased the proportion of S-phase cells, as well as bromodeoxyuridine (BrdU) incorporation compared to their controls. Moreover, serum stimulation experiment revealed that Brd-U positive cells were significantly increased in K562SIRPα1 KD cells. Furthermore, in K562SIRP-α1KD cells, phosphorylation of extracellular regulated kinase (ERK) and Akt was potently increased under low serum conditions. Collectively, these data suggested that down-regulation of SIRPα1 led to the constitutive activation of these aberrant signaling, as well as abnormal growth, in K562 cells.
No takes yet. Share an insight, caveat, or question.
Shinichiro Takahashi (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: